Posted inOncology Pathology & Lab Medicine Specialties
Early ctDNA Variation as a Prognostic Biomarker in dMMR/MSI-H Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors: Insights from the SAMCO-PRODIGE 54 Trial
A secondary analysis of the SAMCO-PRODIGE 54 trial reveals that early changes in circulating tumor DNA predict long-term outcomes in dMMR/MSI-H metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
